Designer drugs

Averix Bio: Avient Biosciences Adopts New Name to Signal Move to 21 CFR Part 210 and Part 211 Compliance

Retrieved on: 
Friday, July 30, 2021
Designer drugs, Euphoriants

"Our goal over the last 18 months has been to introduce a higher level of compliance and manufacturing rigor to cannabinoid production," said Miles Wright, the company's CEO.

Key Points: 
  • "Our goal over the last 18 months has been to introduce a higher level of compliance and manufacturing rigor to cannabinoid production," said Miles Wright, the company's CEO.
  • That experience provides peace-of-mind for premier pharmaceutical manufacturers that need batch samples, "seed-to-shelf" tracing and high levels of compliance.
  • Averix Bio is in process to be the first botanical-based cannabinoid research and extraction company in the U.S. producing 21 CFR Part 210 and Part 211-compliant products.
  • Led by a world-class team with cGMP/pharmaceutical experience, Averix Bio is on a mission to bring healthier cannabinoid-based medical solutions to a global consumer market.

Bereaved Parents Create Non-Profit to Combat Fentanyl Epidemic

Retrieved on: 
Sunday, July 18, 2021
Psychoactive drugs, Anilides, Piperidines, Synthetic opioids, Drugs, Chemical compounds, Designer drugs, Janssen Pharmaceutica, Fentanyl

Fentanyl, a cheap and powerful opioid, is the primary driver of the dramatic increase in drug deaths over the past year, according to the CDC .

Key Points: 
  • Fentanyl, a cheap and powerful opioid, is the primary driver of the dramatic increase in drug deaths over the past year, according to the CDC .
  • "Educating kids and families about the real dangers of fentanyl is just as important as monitoring platforms for drug activity.
  • In addition, Snap will also run a special episode of its award-winning news show, Good Luck America (GLA), devoted to the fentanyl epidemic and featuring an interview with Ed Ternan.
  • "We are honored to partner with Song for Charlie to educate young people on the dangers of counterfeit drugs and fentanyl poisoning.

Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program

Retrieved on: 
Monday, June 14, 2021
Psychoactive drugs, Entheogens, Psychedelic drugs, Ayahuasca, Designer drugs, Mycotoxins, N,N-Dimethyltryptamine, Psilocybin, 5-MeO-DMT, Lysergic acid diethylamide, Psychedelic therapy

The COPE program, launched in March, aims to create the worlds first preclinical behavioral and pharmacokinetics benchmark data for clinically relevant psychedelic drugs including psilocybin, LSD, DMT, and 5-MeO-DMT, amongst others.

Key Points: 
  • The COPE program, launched in March, aims to create the worlds first preclinical behavioral and pharmacokinetics benchmark data for clinically relevant psychedelic drugs including psilocybin, LSD, DMT, and 5-MeO-DMT, amongst others.
  • COPE data is available to InterVivo sponsors via a partnership between Mindset and InterVivo that will allow all parties to benefit from the use of COPE data.
  • The COPE program data sets have been carefully built in partnership with InterVivos industry leading pre-clinical scientific team.
  • For detailed information on the COPE Benchmark data set, please contact Sal Lemus, Director of Sales and Marketing at InterVivo.

ZYUS Life Sciences Partners with Portugal’s Aureuspharma to Further Increase International Patient Access to Medical Cannabinoids

Retrieved on: 
Thursday, May 27, 2021
Pharmaceutical, Alternative medicine, Managed care, Oncology, General Health, Health, Medical devices, Other Health, Cannabinoids, Designer drugs

This is another important milestone in ZYUS mission to improve quality of life for patients globally.

Key Points: 
  • This is another important milestone in ZYUS mission to improve quality of life for patients globally.
  • ZYUS is a leader in exploring the potential of cannabinoids through clinical research to advance the scientific understanding and their role in pain management and other medical solutions.
  • ZYUS is currently working closely with Aureuspharma to finalize all necessary Portuguese and Canadian permitting to make its cannabinoid formulations available to Portuguese patients.
  • About ZYUS Life Sciences Inc.
    ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of innovative cannabinoid-based therapeutics and product candidates.

Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group

Retrieved on: 
Tuesday, May 18, 2021
Psychoactive drugs, Entheogens, Amines, Ayahuasca, N,N-Dimethyltryptamine, Designer drugs, Pharmaceuticals policy

b'Vancouver, British Columbia--(Newsfile Corp. - May 18, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the "Agreement") with Laboratorium Ofichem BV ("Ofichem" or "Ofichem Group").

Key Points: 
  • b'Vancouver, British Columbia--(Newsfile Corp. - May 18, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the "Agreement") with Laboratorium Ofichem BV ("Ofichem" or "Ofichem Group").
  • Under the terms of the Agreement, Ofichem will supply Entheon with GMP quality N,N-dimethyltryptamine drug substances ("DMT") for upcoming formulation, preclinical, clinical, and post-approval commercialization phases under the European Medicines Agency regulatory framework.\nThe Agreement, entered into May 4, 2021, will see Ofichem provide GMP DMT product as well as the required analytical data package for use in the previously announced phase 1 human clinical trial to be conducted by the Centre for Human Drug Research.
  • Ofichem will also provide any additional DMT product that is required for an anticipated stability study.
  • Ofichem\'s significant experience in organic synthesis, analytical chemistry and drug development make them an ideal European partner for this initiative," said Timothy Ko, Chief Executive Officer of Entheon.

CB Therapeutics Closes on Oversubscribed Series A

Retrieved on: 
Monday, May 10, 2021
Research, MEN, General Health, Pharmaceutical, Consumer, Clinical trials, Science, Biotechnology, Alternative medicine, Other Science, Health, Pets, Cannabinoid, Biotechnology, Designer drugs, CB Therapeutics, re.Mind Capital, CB THERAPEUTICS, RE.MIND CAPITAL

Its proprietary cellular agriculture platform enables next generation biosynthetic production of cannabinoids and psychedelic medicines and their analogs to further clinical research for various serious health conditions.

Key Points: 
  • Its proprietary cellular agriculture platform enables next generation biosynthetic production of cannabinoids and psychedelic medicines and their analogs to further clinical research for various serious health conditions.
  • With this new funding, advisors, and the board, we aim to be the leading biotechnology company for the biosynthesis of tryptamines, cannabinoids, and their analogs.\xe2\x80\x9d\n\xe2\x80\x9cThis fresh round of funding for CB Therapeutics will allow us to rapidly accelerate our scaled up manufacturing and sale of cannabinoids and tryptamines,\xe2\x80\x9d said Dr. Jacob Vogan, CSO of CB Therapeutics.
  • The CB Therapeutics platform can not only make the active compounds and phytochemicals that occur naturally, but by using enzymatic processes CB Therapeutics has been able to create bio-identical compounds as well as their analogs.
  • We seek out companies with innovative and highly impactful solutions to our global mental health crisis.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210510005112/en/\n'

Mindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation DMT & 5-MeO-DMT Compounds

Retrieved on: 
Thursday, April 29, 2021
Psychoactive drugs, Branches of biology, Amines, Serotonin receptors, Entheogens, Designer drugs, Ayahuasca, Psychedelic drugs, N,N-Dimethyltryptamine, 5-HT2A receptor, Serotonin, 5-MeO-DMT

DMT & 5-MeO-DMT are attracting growing attention as potential therapeutics for neuropsychiatric indications.

Key Points: 
  • DMT & 5-MeO-DMT are attracting growing attention as potential therapeutics for neuropsychiatric indications.
  • The depth of psychedelic experience that these drugs induce coupled with their relatively short duration of action make them desirable candidates for in-clinic treatment models.
  • These include not only the 5-HT2A receptor subtype, which is well understood to be highly correlated with a psychedelic experience, but also the 5-HT1A and 5-HT2C receptors as well.
  • Mindset\'s proprietary next-generation psychedelic drug pipeline continues to expand and we will provide updates of such expansion at the appropriate time.

Mindset Pharma Files a Sixth U.S. Provisional Patent, Further Expanding Its Psychedelic Drug Candidates Pipeline With Novel DMT & 5-MeO-DMT Analogs

Retrieved on: 
Monday, March 15, 2021
Psychoactive drugs, Amines, Ayahuasca, Entheogens, Designer drugs, N,N-Dimethyltryptamine, 5-MeO-DMT, Tryptamines, Psychedelic drug, 5,6-MDO-DMT, 4-MeO-DMT

This most recent patent application covers a comprehensive range of novel N,N-Dimethyltryptamine ("DMT") and 5-methoxy-N,N-dimethyltryptamine ("5-MeO-DMT") analogs, their related chemical process synthesis, composition of matter and therapeutic uses.

Key Points: 
  • This most recent patent application covers a comprehensive range of novel N,N-Dimethyltryptamine ("DMT") and 5-methoxy-N,N-dimethyltryptamine ("5-MeO-DMT") analogs, their related chemical process synthesis, composition of matter and therapeutic uses.
  • The Mindset scientific advisory board believes that strategic structural modifications to DMT and 5-MeO-DMT could reduce toxicity and metabolic liabilities, resulting in an improved and safer psychedelic therapeutic.
  • Dr. Malik Slassi, a member of Mindset's scientific advisory board noted, "We are very excited to add yet another psychedelic asset to our drug discovery and development program.
  • We look forward to sharing additional updates around both our new drug program as well as our manufacturing process program shortly."

Risk assessment report on a new psychoactive substance: methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dime- thylbutanoate (4F-MDMB-BICA) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

Retrieved on: 
Saturday, March 13, 2021
Designer drugs, Cannabinoids, Organofluorides, European Monitoring Centre for Drugs and Drug Addiction, European Union, 4F-MDMB-BINACA, Risk, Chemistry, Physical sciences, Articles

This risk assessment report presents the summary findings and the conclusion of the risk assessment carried out by the Scientific Committee of the EMCDDA on 4F-MDMB-BICA.

Key Points: 
  • This risk assessment report presents the summary findings and the conclusion of the risk assessment carried out by the Scientific Committee of the EMCDDA on 4F-MDMB-BICA.
  • The report is intended for policymakers and decision-makers in the institutions of the EU.
  • Explanatory note: In the interests of public health protection the EMCDDA is releasing this report before formal copy editing and page layout in the EMCDDA house style.
  • The final report will be available in due course.

Risk Assessment Report on a new psychoactive substance: methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-car- bonyl]amino}butanoate (MDMB-4en-PINACA) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

Retrieved on: 
Saturday, March 13, 2021
Designer drugs, European Monitoring Centre for Drugs and Drug Addiction, European Union, Cannabinoids, Risk, Articles

This risk assessment report presents the summary findings and the conclusion of the risk assessment carried out by the Scientific Committee of the EMCDDA on MDMB-4en- PINACA.

Key Points: 
  • This risk assessment report presents the summary findings and the conclusion of the risk assessment carried out by the Scientific Committee of the EMCDDA on MDMB-4en- PINACA.
  • The report is intended for policymakers and decision-makers in the institutions of the EU.
  • Explanatory note: In the interests of public health protection the EMCDDA is releasing this report before formal copy editing and page layout in the EMCDDA house style.
  • The final report will be available in due course.